Meeting
2021 Gastrointestinal Cancers Symposium
Preliminary results of the phase II ALTER-H003 trial: Anlotinib plus toripalimab as a first-line treatment for patients with unresectable hepatocellular carcinoma.
Authors
Haifeng Lin
The Second Affiliated Hospital of Hainan Medical University, Haikou, China
Haifeng Lin , Jie Ma , Manyun Zhuo , Chengsheng Zhang , Jingru Luo , Xiaohong Zhuang , Zhiming Zeng , Lihua Yang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Hepatobiliary Cancer
Track
Hepatobiliary Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
ChiCTR1900028295
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 314)
DOI
10.1200/JCO.2021.39.3_suppl.314
Abstract #
314
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Anlotinib plus toripalimab as first-line treatment for patients with unresectable hepatocellular carcinoma: Updated results of the ALTER-H003 trial.
First Author: Haifeng Lin
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Updated results of the phase II ALTER-H003 trial: Anlotinib plus toripalimab as a first-line treatment for patients with unresectable hepatocellular carcinoma.
First Author: Haifeng Lin
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Second-line regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) after progression on first-line atezolizumab plus bevacizumab (Atezo-Bev): Phase 2 REGONEXT trial.
First Author: Changhoon Yoo
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Fruquintinib combined with sintilimab plus transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma: A single-arm phase II study.
First Author: Guoliang Shao